Amylyx Pharmaceuticals, Inc. (AMLX) |
|
36.08 -0.92 (-2.49%)
|
02-03 14:15 |
|
Open: |
36.67 |
Pre. Close: |
37 |
|
High:
|
37.38 |
Low:
|
36.02 |
|
Volume:
|
320,590 |
Market Cap:
|
2,391(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 1:44:36 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
| Target: |
Six months: 44.86 One year: 48.96 |
| Support: |
Support1: 32.74 Support2: 27.24 |
| Resistance: |
Resistance1: 38.41 Resistance2: 41.91 |
| Pivot: |
38.34  |
| Moving Average: |
MA(5): 38.58 MA(20): 37.86
MA(100): 35.11 MA(250): 25.26 |
| MACD: |
MACD(12,26): 0.5 Signal(9): 0.7 |
| Stochastic oscillator: |
%K(14,3): 52.9 %D(3): 64.4 |
| RSI: |
RSI(14): 44.9 |
| 52-week: |
High: 41.91 Low: 6.51 |
| Average Vol(K): |
3-Month: 785 (K) 10-Days: 783 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AMLX ] has closed above bottom band by 25.2%. Bollinger Bands are 14.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
40.93 - 41.13 |
41.13 - 41.32 |
|
Low:
|
35.16 - 35.39 |
35.39 - 35.61 |
|
Close:
|
36.57 - 36.94 |
36.94 - 37.3 |
|
Company Description |
|
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Thu, 02 Feb 2023
2023-02-02 | NDAQ:AMLX | Press Release | Amylyx ... - Stockhouse
Mon, 30 Jan 2023
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average ... - MarketBeat
Wed, 25 Jan 2023
With 40% ownership in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), institutional investors have a lot riding on the business - Simply Wall St
Wed, 25 Jan 2023
Kestra Advisory Services LLC Invests $1.20 Million in Amylyx ... - MarketBeat
Thu, 19 Jan 2023
Can Amylyx Pharmaceuticals Inc (AMLX) Stock Rise to the Top of Healthcare Sector Thursday? - InvestorsObserver
Tue, 17 Jan 2023
Amylyx Pharmaceuticals Announces Exclusive AMX0035 ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
3.083e+007 (%) |
|
% Held by Institutions
|
24.9 (%) |
|
Shares Short
|
3,680 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.5313e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-53 |
|
Return on Assets (ttm)
|
789.4 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
285000 |
|
Gross Profit (p.s.)
|
-0.43 |
|
Sales Per Share
|
0.01 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-136 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
0 |
|
Price to Sales
|
3237.9 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
6.7e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
